Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Allergan enters marketing agreement with McNeil for ophthalmic ofloxacin

Sep. 17, 1999

Ciba Vision and QLT initiate T-IND clinical program for Visudyne therapy

Sep. 14, 1999

InSite Vision receives milestone payment for ISV-205 development

Sep. 9, 1999

Cambridge Antibody Technology reports positive initial results from CAT-152 trial

Sep. 7, 1999

NOS-2 inhibition with aminoguanidine prevents vision loss in rat model of glaucoma

Sep. 6, 1999

KeraVision receives FDA approval to complete enrollment for phase IIIb Intacs trial

Sep. 1, 1999

Alcon introduces ocular antiinflammatory agent in Germany

Aug. 27, 1999

Alcon suspends distribution of ophthalmic NSAIDs

Aug. 26, 1999

FDA grants priority review to Visudyne NDA

Aug. 25, 1999

Allergan receives approvable letter for Restasis

Aug. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...